(2S)-1-[(2S)-2-formylpyrrolidin-1-yl]pyrrolidine-2-carbaldehyde

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2S)-1-[(2S)-2-formylpyrrolidin-1-yl]pyrrolidine-2-carbaldehyde
• 化学式: C₁₀H₁₆N₂O₂
• 分子量: 196.25
• InChiKey: MSUAYGDPTIJKLH-UWVGGRQHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  40.6
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• PRODUCTION METHOD FOR CASEIN-DERIVED PEPTIDES BY LACTIC ACID FERMENTATION
  申请人：Calpis Co., Ltd.

  公开号：EP2735616A1

  公开（公告）日：2014-05-28

  The present invention provides a simple and efficient method for preparing safer compounds which prevent and ameliorate conditions and diseases caused by reduction in brain function and are suitable for use in medicines and food products. Specifically, the present invention provides: a method for preparing peptides each consisting of an amino acid sequence shown in any of SEQ ID NOs: 1-4 or 16, said method being characterized in that mammalian milk or milk protein is fermented using at least one lactic acid bacterium and/or a processed product thereof, and then the peptides are collected from the resultant fermented milk.

  本发明提供了一种简单有效的方法，用于制备更安全的化合物，该化合物可预防和改善由脑功能减退引起的病症和疾病，适用于药物和食品。具体地说，本发明提供了：一种制备肽的方法，所述肽由 SEQ ID NO：1-4 或 16 中任意一个所示的氨基酸序列组成，所述方法的特征在于，使用至少一种乳酸菌和/或其加工产品发酵哺乳动物乳或乳蛋白，然后从发酵后的乳中收集肽。
• MONOCYCLIC PYRIDINE DERIVATIVE
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2960238A1

  公开（公告）日：2015-12-30

  The present invention discloses a compound represented by the following formula (IA) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or -CH2-; E represents a nitrogen-containing non-aromatic heterocycle; R1 represents an alkoxy group, an alkoxy alkoxy group or the like; R2 represents a hydrogen atom, a halogen atom, a hydroxyl group, an alkyl group, a hydroxy alkyl group, a nitrogen-containing non-aromatic heterocyclic group or the like; R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like; and R4 represents a C1-6 alkyl group, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.

  本发明公开了由下式（IA）代表的化合物或其药学上可接受的盐： 其中 n 代表 0 至 2；A 代表芳基或杂芳基；G 代表单键、氧原子或-CH2-；E 代表含氮非芳香杂环；R1 代表烷氧基、烷氧基烷氧基或类似物；R2 代表氢原子、卤素原子、羟基、烷基、羟基烷基、含氮非芳香杂环基团或类似物；R3 代表氢原子、烷基、烷氧基或类似基团；以及 R4 代表 C1-6 烷基，但当 E 代表氮杂环丁烷环且 R2 或 R3 存在于氮杂环丁烷环上的氮原子上时，R2 或 R3 不代表氢原子。
• DETECTING AND PROFILING MOLECULAR COMPLEXES
  申请人：Monogram BioSciences, Inc.

  公开号：EP1673399B1

  公开（公告）日：2017-04-05
• OXAZOLIDINONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
  申请人：Itai Akiko

  公开号：US20110294813A1

  公开（公告）日：2011-12-01

  Disclosed is a compound which is useful as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein R 1 is optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocycle or optionally substituted heterocyclealkyl, X is —O—, —NR 3 —, —NR 3 C(═O)— or —NR 3 S(═O) 2 —, R 2 is optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl, R 3 is hydrogen or optionally substituted alkyl.
• SOLID PHASE PEPTIDE SYNTHESIS VIA SIDE CHAIN ATTACHMENT
  申请人：Chemical & Biopharmaceutical Laboratories of Patras S.A.

  公开号：US20140235789A1

  公开（公告）日：2014-08-21

  The present application discloses peptides and peptaibols of high purity may be obtained by solid phase peptide synthesis using as the starting resin hydroxy amino acids, hydroxy amino acid amides, hydroxy amino alcohols or small peptides containing hydroxy amino acids attached to polymers through their side chain.